Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THVâs single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Companyâs ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
äŒæ¥ã³ãŒãAVR
äŒç€ŸåAnteris Technologies Global Corp
äžå Žæ¥Dec 13, 2024
æé«çµå¶è²¬ä»»è
ãCEOãPaterson (Wayne G)
åŸæ¥å¡æ°136
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 13
æ¬ç€Ÿæåšå°860 Blue Gentian Road
éœåžEAGAN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·55121
é»è©±çªå·16514930606
ãŠã§ããµã€ãhttps://anteristech.com/
äŒæ¥ã³ãŒãAVR
äžå Žæ¥Dec 13, 2024
æé«çµå¶è²¬ä»»è
ãCEOãPaterson (Wayne G)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã